BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2021

View Archived Issues

Sanofi selects NK cell engager IPH-6101 as drug candidate

Read More

ApoE multitasks for regulating brain lipids

Read More

Extension study results of patisiran in transthyretin-related amyloid polyneuropathy presented

Read More

HDGF is a therapeutic target in hepatitis

Read More

FDA clears IND for phase I trial of PRGN-2012 for recurrent respiratory papillomatosis

Read More

Vir initiates phase I trial of HIV T-cell vaccine VIR-1111

Read More

Activating NK cells without interleukins

Read More

Dosing initiates in phase IIa study of MET-409 plus empagliflozin in patients with T2DM and NASH

Read More

First patient dosed in phase I study of Replimune's third clinical candidate, RP-3

Read More

Topline data presented from phase III KEEPsAKE studies of risankizumab

Read More

HELIOS-A phase III study of vutrisiran meets its primary and secondary endpoints

Read More

FDA approves IND for phase IIb study of orismilast in patients with plaque psoriasis

Read More

REGENXBIO announces development updates for RGX-314 and RGX-202

Read More

Beijing Reciproca Pharmaceuticals patents new CDK inhibitors

Read More

Chinese researchers presents new SERCAs for breast cancer

Read More

GlaxoSmithKline plc discloses new antibacterials

Read More

LY-CoV555 does not show efficacy in hospitalized patients with COVID-19

Read More

Pfizer and CTxT Pty synthesize KAT inhibitors

Read More

Penciling in the right base corrects progeria mutation

Read More

ViiV Healthcare discovers compounds for HIV infection

Read More

Phase III induction studies of risankizumab in Crohn's disease meet primary endpoints

Read More

AstraZeneca's COVID-19 vaccine receives further emergency use authorizations

Read More

Aldeyra reports topline phase III data on reproxalap in dry eye disease

Read More

REMD reports phase II topline data on volagidemab in type 1 diabetes

Read More

Phase III RISE trial of TV-46000 in schizophrenia meets primary endpoint

Read More

NorthSea reports interim phase IIb data on icosabutate in NASH

Read More

Part 1 topline data reported from trial of SRP-9001 in Duchenne muscular dystrophy

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing